Lilly’s weight loss pill Foundayo now available in U.S.

Pharmaceutical giant Eli Lilly and Company has officially launched its new oral weight-loss medication, Foundayo, in the United States, following its recent approval by the U.S. Food and Drug Administration (FDA). The introduction marks a significant expansion in the highly competitive market for GLP-1 receptor agonist drugs, which have revolutionized obesity treatment. Lilly's strategic move is aimed at capturing a substantial share of the multi-billion dollar market, currently dominated by injectable treatments like its own Mounjaro and Novo Nordisk's Wegovy, by offering a more convenient pill-based alternative. The launch of Foundayo represents a pivotal moment for both the company and patients. For Eli Lilly, it diversifies its portfolio in a therapeutic area where it is already a leader, potentially driving significant revenue growth. Analysts project the global obesity drug market could exceed $100 billion annually by the end of the decade, and an effective oral medication is seen as key to expanding patient access and adherence compared to weekly injections. The drug's mechanism, similar to other GLP-1 agonists, works by mimicking gut hormones to suppress appetite and slow stomach emptying. Patient access and pricing will be critical factors in Foundayo's commercial success. While the exact list price has not been publicly detailed, it is expected to command a premium, likely in line with other branded GLP-1 therapies that can cost over $1,000 per month without insurance coverage. The company is expected to engage in negotiations with pharmacy benefit managers and insurers, and may offer patient assistance programs to mitigate out-of-pocket costs. Its availability could intensify the ongoing supply challenges and competitive dynamics within the weight-loss drug sector, prompting responses from rivals like Novo Nordisk, which is also developing its own oral version, amycretin.